Lycia Therapeutics (LYCA) 10% Owner L.P. Buys $35M of Stock
Key Points
- Venrock Healthcare increased its stake in Lycia Therapeutics by 1,952,705 shares, bringing its total ownership to about 6.79 million shares.
- After the trade, Venrock Healthcare Capital Partners III, L.P. indirectly holds 6,785,437 $LYCA shares, up 40.41% from before the trade.
- The recent share price of Lycia Therapeutics is around $26.11, which is below both the 50-day and 200-day moving averages by 11.3%.
- Lycia Therapeutics currently has no dividend yield and reported trailing twelve-month revenue of about $4.4 million.
Since the trade, $LYCA is down 9.5% to date (from the $28.85 close on Oct 26, 2026).
Get Lycia Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $LYCA.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Lycia Therapeutics, Inc. alert may contain errors. Disclosures
On October 26, 2026, Venrock Healthcare Capital Partners III, L.P. bought 1,952,705 shares of Lycia Therapeutics, Inc. (LYCA) for about $35.2 million. This purchase was filed with the SEC and marks a significant increase in their stake, raising their total ownership to approximately 6.79 million shares, a 40.41% increase.
LYCA
Lycia Therapeutics, Inc.
Venrock Healthcare Capital Partners III, L.P. vs. the S&P 500
Hypothetical returns from Venrock Healthcare Capital Partners III, L.P.'s disclosed trades, not real profit or advice. How we model this.
What Changed in Venrock Healthcare's Lycia Therapeutics Position
Venrock Healthcare's recent transaction shows a strong commitment to Lycia Therapeutics. The firm acquired 1,952,705 shares at an average price of $18.04 per share. The total value of the shares purchased amounts to about $35.2 million. This move reflects the firm's confidence in the company's future prospects.
Other Institutional Activity in Lycia Therapeutics
There are currently no reports of other institutional activity in Lycia Therapeutics. Venrock Healthcare's transaction stands out as a significant movement in the company's ownership landscape.
Lycia Therapeutics, Inc. Stock Down 9.5%
As of October 27, 2026, Lycia Therapeutics shares are trading around $26.11. This price is below both its 50-day and 200-day moving averages by 11.3%. Additionally, the stock is about 28.4% off its 52-week high of $36.49, but it remains about 17.7% above its 52-week low of $22.19. These figures suggest that the stock is currently underperforming relative to its historical averages.
Recent Earnings
Lycia Therapeutics reported trailing twelve-month revenue of approximately $4.4 million. The company is still in the early stages of its growth, focusing on developing therapeutics for autoimmune and inflammatory diseases. It has not yet turned a profit, with an EPS of -$1.04.
Dividend
Lycia Therapeutics does not currently pay a dividend, as indicated by a dividend yield of 0%. This is consistent with many biotechnology firms that reinvest profits into research and development rather than distributing them to shareholders.
Insider Buying and Selling at Lycia Therapeutics, Inc.
This lack of insider trading activity suggests that the focus remains on external institutional investment.
Analysts Set New Price Targets
The absence of analyst coverage may indicate that the stock is still under the radar for many investment firms.
About Lycia Therapeutics
Lycia Therapeutics, Inc. is a biotechnology company based in South San Francisco, California. It focuses on discovering and developing therapeutics that target disease-causing extracellular proteins for treating autoimmune, inflammatory, and allergic diseases. The company utilizes its LYTAC platform to create innovative treatments aimed at reducing harmful protein levels.
Bottom Line
Investors will be watching how Lycia Therapeutics navigates its development path and whether it can turn its promising technology into profitable products. With no upcoming earnings announcements or significant analyst coverage, the focus will likely remain on institutional movements like Venrock Healthcare's recent buy.
Related Filing Alerts
Source: Venrock Healthcare Capital Partners III, L.P.'s Form 4 filing on $LYCA (Oct 26, 2026). Written by software, not financial advice. How we make alerts